Company news

Grifols, S.A. news in 2026

Grifols, S.A.'s news releases, calls and decks from 2026, newest first.

View company

Grifols S A increases revenue by 8.4% to EUR 2,040 million and grows net profit by 28% to EUR 162m in Q3’26

November 2, 2026

Grifols S A signs renewable energy purchase agreement with ENGIE to cover more than half of its electricity consumption in Spain

September 16, 2026

Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency

August 10, 2026

Grifols S A doses first patients in two Phase 3 trials to expand indications of its flagship immunoglobulins

July 16, 2026

Grifols S A doses first participant in Phase 3 study evaluating novel subcutaneous therapy for alpha1-antitrypsin deficiency

June 29, 2026

Shareholders approve key resolutions at the 2026 Annual General Shareholders’ Meeting

June 18, 2026

Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.

June 15, 2026

Grifols: Egypt continues its growth plan through 2029 with an additional investment of €180 million

June 12, 2026

Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1

June 5, 2026

Grifols S A breaks ground on new manufacturing site in Spain

June 3, 2026

Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease

March 17, 2026

Health Coalition demands disclosures & end to Grifols’ for-profit blood plasma contract following reports of deaths, harm, non-compliance

March 13, 2026

Media Advisory: Press Conference Regarding Tragic Deaths After Plasma Harvesting at Grifols’ Sites

March 12, 2026

Calls in 2026

Decks in 2026